The european male ageing study (EMAS)

Design, methods and recruitment

David M. Lee, Terence W. O'neill, Stephen R. Pye, Alan J. Silman, Joseph D. Finn, Neil Pendleton, Abdelouahid Tajar, G. Bártfai, Felipe Casanueva, Gianni Forti, Aleksander Giwercman, Ilpo T. Huhtaniemi, Krzysztof Kula, Margus Punab, Steven Boonen, Dirk Vanderschueren, Frederick C W Wu

Research output: Contribution to journalArticle

102 Citations (Scopus)

Abstract

Summary Life expectancy is increasing in most developed countries, in part due to improved socioeconomic conditions and in part to advances in healthcare. It is widely acknowledged that the promotion of healthy ageing by delaying, minimizing or preventing disabilities or diseases is one of the most important public health objectives in this century. In contrast to the menopausal transition in females, we know relatively little about the contribution of androgens and anabolic hormones to the quality of ageing in men. The European Male Ageing Study (EMAS) is a multicentre prospective cohort designed to examine the prevalence, incidence and geographical distribution of gender-specific and general symptoms of ageing in men, including their endocrine, genetic and psychosocial predictors. Men aged 40-79 years were recruited from eight European centres: Florence (Italy), Leuven (Belgium), Lodz (Poland), Malmö (Sweden), Manchester (UK), Santiago de Compostela (Spain), Szeged (Hungary) and Tartu (Estonia). Subjects were recruited from population registers and those who agreed to take part completed a detailed questionnaire including aspects of personal and medical history, lifestyle factors and sexual function. Objective measures of body size, cognition, vision, skeletal health and neuromuscular function were obtained. Blood and DNA specimens were collected for a range of biochemical and genetic analyses. After an average of 4 years, it is planned to resurvey the participants with similar assessments. A total of 3369 men with a mean age of 60 ± 11 years were recruited. The mean centre response rate was 43%, and highest in those aged 50-59 years. Those who participated were marginally younger than those who were invited but declined to participate (60.0 vs. 61.1 years). Participants left education slightly later than a sample of non-participants, though there were no consistent differences in levels of general health, physical activity, or smoking. EMAS will provide new population-based data concerning the main features that characterize ageing in men and its critical determinants, particularly with reference to age-related changes in hormone levels. Such information is an important prerequisite to develop effective strategies to reduce age-related disabilities and optimise health and well-being into old-age.

Original languageEnglish
Pages (from-to)11-24
Number of pages14
JournalInternational Journal of Andrology
Volume32
Issue number1
DOIs
Publication statusPublished - Feb 2009

Fingerprint

Hormones
Estonia
Hungary
Belgium
Health
Body Size
Poland
Life Expectancy
Developed Countries
Sweden
Spain
Cognition
Italy
Androgens
Health Status
Registries
Life Style
Molecular Biology
Public Health
Smoking

Keywords

  • Ageing
  • EMAS study
  • Epidemiology
  • Male health
  • Population survey
  • Testosterone

ASJC Scopus subject areas

  • Urology
  • Reproductive Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Lee, D. M., O'neill, T. W., Pye, S. R., Silman, A. J., Finn, J. D., Pendleton, N., ... Wu, F. C. W. (2009). The european male ageing study (EMAS): Design, methods and recruitment. International Journal of Andrology, 32(1), 11-24. https://doi.org/10.1111/j.1365-2605.2008.00879.x

The european male ageing study (EMAS) : Design, methods and recruitment. / Lee, David M.; O'neill, Terence W.; Pye, Stephen R.; Silman, Alan J.; Finn, Joseph D.; Pendleton, Neil; Tajar, Abdelouahid; Bártfai, G.; Casanueva, Felipe; Forti, Gianni; Giwercman, Aleksander; Huhtaniemi, Ilpo T.; Kula, Krzysztof; Punab, Margus; Boonen, Steven; Vanderschueren, Dirk; Wu, Frederick C W.

In: International Journal of Andrology, Vol. 32, No. 1, 02.2009, p. 11-24.

Research output: Contribution to journalArticle

Lee, DM, O'neill, TW, Pye, SR, Silman, AJ, Finn, JD, Pendleton, N, Tajar, A, Bártfai, G, Casanueva, F, Forti, G, Giwercman, A, Huhtaniemi, IT, Kula, K, Punab, M, Boonen, S, Vanderschueren, D & Wu, FCW 2009, 'The european male ageing study (EMAS): Design, methods and recruitment', International Journal of Andrology, vol. 32, no. 1, pp. 11-24. https://doi.org/10.1111/j.1365-2605.2008.00879.x
Lee, David M. ; O'neill, Terence W. ; Pye, Stephen R. ; Silman, Alan J. ; Finn, Joseph D. ; Pendleton, Neil ; Tajar, Abdelouahid ; Bártfai, G. ; Casanueva, Felipe ; Forti, Gianni ; Giwercman, Aleksander ; Huhtaniemi, Ilpo T. ; Kula, Krzysztof ; Punab, Margus ; Boonen, Steven ; Vanderschueren, Dirk ; Wu, Frederick C W. / The european male ageing study (EMAS) : Design, methods and recruitment. In: International Journal of Andrology. 2009 ; Vol. 32, No. 1. pp. 11-24.
@article{6b615f0920e1428a82433371aa5b1cf9,
title = "The european male ageing study (EMAS): Design, methods and recruitment",
abstract = "Summary Life expectancy is increasing in most developed countries, in part due to improved socioeconomic conditions and in part to advances in healthcare. It is widely acknowledged that the promotion of healthy ageing by delaying, minimizing or preventing disabilities or diseases is one of the most important public health objectives in this century. In contrast to the menopausal transition in females, we know relatively little about the contribution of androgens and anabolic hormones to the quality of ageing in men. The European Male Ageing Study (EMAS) is a multicentre prospective cohort designed to examine the prevalence, incidence and geographical distribution of gender-specific and general symptoms of ageing in men, including their endocrine, genetic and psychosocial predictors. Men aged 40-79 years were recruited from eight European centres: Florence (Italy), Leuven (Belgium), Lodz (Poland), Malm{\"o} (Sweden), Manchester (UK), Santiago de Compostela (Spain), Szeged (Hungary) and Tartu (Estonia). Subjects were recruited from population registers and those who agreed to take part completed a detailed questionnaire including aspects of personal and medical history, lifestyle factors and sexual function. Objective measures of body size, cognition, vision, skeletal health and neuromuscular function were obtained. Blood and DNA specimens were collected for a range of biochemical and genetic analyses. After an average of 4 years, it is planned to resurvey the participants with similar assessments. A total of 3369 men with a mean age of 60 ± 11 years were recruited. The mean centre response rate was 43{\%}, and highest in those aged 50-59 years. Those who participated were marginally younger than those who were invited but declined to participate (60.0 vs. 61.1 years). Participants left education slightly later than a sample of non-participants, though there were no consistent differences in levels of general health, physical activity, or smoking. EMAS will provide new population-based data concerning the main features that characterize ageing in men and its critical determinants, particularly with reference to age-related changes in hormone levels. Such information is an important prerequisite to develop effective strategies to reduce age-related disabilities and optimise health and well-being into old-age.",
keywords = "Ageing, EMAS study, Epidemiology, Male health, Population survey, Testosterone",
author = "Lee, {David M.} and O'neill, {Terence W.} and Pye, {Stephen R.} and Silman, {Alan J.} and Finn, {Joseph D.} and Neil Pendleton and Abdelouahid Tajar and G. B{\'a}rtfai and Felipe Casanueva and Gianni Forti and Aleksander Giwercman and Huhtaniemi, {Ilpo T.} and Krzysztof Kula and Margus Punab and Steven Boonen and Dirk Vanderschueren and Wu, {Frederick C W}",
year = "2009",
month = "2",
doi = "10.1111/j.1365-2605.2008.00879.x",
language = "English",
volume = "32",
pages = "11--24",
journal = "International Journal of Andrology",
issn = "0105-6263",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - The european male ageing study (EMAS)

T2 - Design, methods and recruitment

AU - Lee, David M.

AU - O'neill, Terence W.

AU - Pye, Stephen R.

AU - Silman, Alan J.

AU - Finn, Joseph D.

AU - Pendleton, Neil

AU - Tajar, Abdelouahid

AU - Bártfai, G.

AU - Casanueva, Felipe

AU - Forti, Gianni

AU - Giwercman, Aleksander

AU - Huhtaniemi, Ilpo T.

AU - Kula, Krzysztof

AU - Punab, Margus

AU - Boonen, Steven

AU - Vanderschueren, Dirk

AU - Wu, Frederick C W

PY - 2009/2

Y1 - 2009/2

N2 - Summary Life expectancy is increasing in most developed countries, in part due to improved socioeconomic conditions and in part to advances in healthcare. It is widely acknowledged that the promotion of healthy ageing by delaying, minimizing or preventing disabilities or diseases is one of the most important public health objectives in this century. In contrast to the menopausal transition in females, we know relatively little about the contribution of androgens and anabolic hormones to the quality of ageing in men. The European Male Ageing Study (EMAS) is a multicentre prospective cohort designed to examine the prevalence, incidence and geographical distribution of gender-specific and general symptoms of ageing in men, including their endocrine, genetic and psychosocial predictors. Men aged 40-79 years were recruited from eight European centres: Florence (Italy), Leuven (Belgium), Lodz (Poland), Malmö (Sweden), Manchester (UK), Santiago de Compostela (Spain), Szeged (Hungary) and Tartu (Estonia). Subjects were recruited from population registers and those who agreed to take part completed a detailed questionnaire including aspects of personal and medical history, lifestyle factors and sexual function. Objective measures of body size, cognition, vision, skeletal health and neuromuscular function were obtained. Blood and DNA specimens were collected for a range of biochemical and genetic analyses. After an average of 4 years, it is planned to resurvey the participants with similar assessments. A total of 3369 men with a mean age of 60 ± 11 years were recruited. The mean centre response rate was 43%, and highest in those aged 50-59 years. Those who participated were marginally younger than those who were invited but declined to participate (60.0 vs. 61.1 years). Participants left education slightly later than a sample of non-participants, though there were no consistent differences in levels of general health, physical activity, or smoking. EMAS will provide new population-based data concerning the main features that characterize ageing in men and its critical determinants, particularly with reference to age-related changes in hormone levels. Such information is an important prerequisite to develop effective strategies to reduce age-related disabilities and optimise health and well-being into old-age.

AB - Summary Life expectancy is increasing in most developed countries, in part due to improved socioeconomic conditions and in part to advances in healthcare. It is widely acknowledged that the promotion of healthy ageing by delaying, minimizing or preventing disabilities or diseases is one of the most important public health objectives in this century. In contrast to the menopausal transition in females, we know relatively little about the contribution of androgens and anabolic hormones to the quality of ageing in men. The European Male Ageing Study (EMAS) is a multicentre prospective cohort designed to examine the prevalence, incidence and geographical distribution of gender-specific and general symptoms of ageing in men, including their endocrine, genetic and psychosocial predictors. Men aged 40-79 years were recruited from eight European centres: Florence (Italy), Leuven (Belgium), Lodz (Poland), Malmö (Sweden), Manchester (UK), Santiago de Compostela (Spain), Szeged (Hungary) and Tartu (Estonia). Subjects were recruited from population registers and those who agreed to take part completed a detailed questionnaire including aspects of personal and medical history, lifestyle factors and sexual function. Objective measures of body size, cognition, vision, skeletal health and neuromuscular function were obtained. Blood and DNA specimens were collected for a range of biochemical and genetic analyses. After an average of 4 years, it is planned to resurvey the participants with similar assessments. A total of 3369 men with a mean age of 60 ± 11 years were recruited. The mean centre response rate was 43%, and highest in those aged 50-59 years. Those who participated were marginally younger than those who were invited but declined to participate (60.0 vs. 61.1 years). Participants left education slightly later than a sample of non-participants, though there were no consistent differences in levels of general health, physical activity, or smoking. EMAS will provide new population-based data concerning the main features that characterize ageing in men and its critical determinants, particularly with reference to age-related changes in hormone levels. Such information is an important prerequisite to develop effective strategies to reduce age-related disabilities and optimise health and well-being into old-age.

KW - Ageing

KW - EMAS study

KW - Epidemiology

KW - Male health

KW - Population survey

KW - Testosterone

UR - http://www.scopus.com/inward/record.url?scp=58149289753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149289753&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2605.2008.00879.x

DO - 10.1111/j.1365-2605.2008.00879.x

M3 - Article

VL - 32

SP - 11

EP - 24

JO - International Journal of Andrology

JF - International Journal of Andrology

SN - 0105-6263

IS - 1

ER -